Larimar Therapeutics, Inc. — Director's Dealing 2017

Feb 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2017-02-13

Reporting Person: Daniel Thomas O (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-13	Common Stock	A	10765	$4.18	Acquired	10765	Direct

Footnotes

F1: The common stock was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Restricted Stock Agreement and the restrictions lapse over a period of one year starting January 1, 2017 on quarterly basis in arrears.